Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Kansas City, Kansas 66160


This is a continuation study to KUDOS (NCT00266825). The purpose of this study is to follow-up with participants on the original study to determine if the effects of increasing DHA intake during pregnancy increase cognitive development in 2 to 6 year-old children.

Study summary:

Numerous trials show benefits of postnatal DHA supplementation for visual acuity. There are also numerous observational(not intervention)studies that link higher maternal DHA status during pregnancy to higher cognitive function. Intervention studies that increase DHA exposure during fetal life and that measure cognitive development of infants are lacking; and no study to date has systematically followed children whose mothers were randomly assigned to DHA supplementation to school age with regular 6 month assessments of age-appropriate assessments of cognitive development. The absence of such studies is a serious limitation because there is evidence that differences in cognitive function due to such interventions do not become robust until around age 4 years. Women in the US consume low amounts of DHA compared to other world populations, and this likely means less DHA transfer to the fetus than in many other populations. Prenatal DHA exposure may be more important than postnatal exposure, because animal studies show critical windows for brain DHA accumulation in relation to effects on neurotransmitters such as serotonin, dopamine and GABA.


Inclusion Criteria: - Pregnant females 16.0-35.0 years of age (inclusive) at 8-20 weeks gestation at enrollment (date/ultrasound) - Agree to consume study capsules from enrollment until delivery - Agree to return to the study center for delivery - BMI < 40 - No serious illnesses (e.g., cancer, diabetes, lupus, hepatitis, sexually transmitted diseases, not HIV positive) - Available by telephone Exclusion Criteria: - Less than 16 or greater than 35 years of age - BMI < 40 - Serious illness such as cancer, lupus, hepatitis, sexually transmitted disease or HIV positive - Expecting multiple infants - Diabetes or gestational diabetes at baseline - Elevated blood pressure due to any cause - Not planning to return to the study center for delivery - Gestational age at baseline < 8 weeks or >20 weeks - Unable or unwilling to agree to consume capsules until delivery - Unable to provide informed consent in English



Primary Contact:

Principal Investigator
Susan E Carlson, PhD
University of Kansas Medical Center

Backup Contact:


Location Contact:

Kansas City, Kansas 66160
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.